Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Herpes Zoster
- Sponsor
- GlaxoSmithKline
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of GSK Biologicals' Herpes Zoster (HZ) vaccine (GSK 1437173A) when administered subcutaneously (SC) as compared to intramuscularly (IM) to people 50 years of age and older.
Detailed Description
There are 2 treatment groups in this study based upon the mode of vaccine administration. The humoral immunogenicity (HI) will be measured in all subjects.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •Subject, residing in Japan, is of Japanese ethnic origin, defined as having been born in Japan with four ethnic Japanese grandparents and able to speak Japanese.
- •Subject has provided written informed consent.
- •Subject, male or female, who is 50 YOA or older at the time of the first vaccination.
- •Subject, if female, of non-childbearing potential may be enrolled in the study.
- •Subject, if female, of childbearing potential may be enrolled in the study, if the subject:
- •has practiced adequate contraception for 30 days prior to vaccination, and
- •has a negative pregnancy test on the day of vaccination, and
- •has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series (i.e., for 2 months after Month 2).
Exclusion Criteria
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Concurrently participating or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
- •Administration or planned administration of a live vaccine within 30 days prior to the first study vaccination through 30 days after the second study vaccination.
- •Administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
- •Planned administration, during the study, of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine.
- •Administration of immunoglobulins and/or any blood products within the three (3) months preceding the first dose of study vaccine or planned administration during the study period.
- •Chronic administration (defined as \>14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •For corticosteroids, a prednisone dose of \<20 mg/day, or equivalent, is allowed.
- •Inhaled, topical, and intra-articular corticosteroids are allowed.
- •Administration or planned administration of long-acting immune-modifying drugs (e.g., infliximab) within six months prior to the first vaccine dose through the duration of the study period.
Outcomes
Primary Outcomes
Number of Subjects With Anti-Glycoprotein E (Anti-gE) Antibody Concentrations Higher Than or Equal to (≥)18 Milli-international Units Per Milliliter (mIU/mL)
Time Frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
A seropositive subject was defined as a subject whose anti-gE Ab concentration was greater than or equal to the assay cut-off value, of 18 mIU/mL.
Anti-gE Antibody Concentrations
Time Frame: Before vaccination (PRE), two months after Dose 1 (M2) and one month after Dose 2 (M3)
Anti-gE antibody concentrations were expressed as geometric mean concentrations (GMCs) and measured in mIU/mL.
Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations
Time Frame: At two months after Dose 1 (M2) and one month after Dose 2 (M3)
Vaccine response was defined as: For initially seronegative subjects, antibody concentration at post-vaccination ≥ 4 fold the cut-off for Anti-gE (4x18 mIU/mL); for initially seropositive subjects, antibody concentration at post-vaccination ≥ 4 fold the pre-vaccination antibody concentration.
Number of Subjects With Solicited Local Symptoms
Time Frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
The solicited local symptoms assessed were: Arm movement/range of motion of the vaccinated arm, Injection site pruritus, Pain, Redness, and Swelling. Any = occurrence of any local symptom regardless of their intensity grade. Grade 3 Pain = Significant pain at rest that prevented normal every day activities. Grade 3 Injection site pruritus = Significant pruritus that prevented normal every day activities. Grade 3 impairment of arm movement/range of motion = Significant impairment of arm movement/range of motion that prevented normal every day activities.
Descriptive Statistics of Anti-gE Antibody Concentrations
Time Frame: Before vaccination (PRE), at two months after dose 1 (M2) and one month after Dose 2 (M3)
Anti-gE antibody concentrations were assessed by the Enzyme Lynked Immunosorbent Assay.
Number of Subjects With Solicited General Symptoms
Time Frame: During the 7 day (Days 0-6) post vaccination, after each dose (D) and across doses
Assessed solicited general symptoms were: Fatigue, Fever, Gastrointestinal (nausea, vomiting, diarrhea and/or abdominal pain), Headache, Myalgia, and Shivering. Fever = axillary temperature ≥37.5°C. Any = occurrence of any general symptoms regardless of their intensity grade or relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 Fever = axillary temperature higher than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to vaccination.
Mean Number of Days With Local Symptoms
Time Frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)
Days with solicited local symptoms were tabulated for the total vaccinated cohort.
Mean Number of Days With General Symptoms
Time Frame: During the 7 day (Days 0-6) post vaccination, after each dose (D)
Days with solicited general symptoms were tabulated for the total vaccinated cohort.
Number of Subjects With Unsolicited Adverse Events (AEs)
Time Frame: Within 30 days (Days 0-29) post vaccination period
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Number of Subjects With Potential Immune-Mediated Disorders (pIMDs)
Time Frame: From Month 0 to Month 3
Potential immune-mediated diseases (pIMDs) were a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Number of Subjects With Serious Adverse Events (SAEs)
Time Frame: From Month 0 to Month 3
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Secondary Outcomes
- Number of Subjects With Anti-gE Antibody Concentrations ≥ 97 mIU/mL(At Month 14)
- Anti-gE Antibody Concentrations(At Month 14)
- Number of Subjects With Vaccine Response for Anti-gE Antibody Concentrations(Twelve Months after Dose 2 (M14))
- Number of Subjects With pIMDs(Up to Month 14 post vaccination period)
- Number of Subjects With SAEs(Up to Month 14 post vaccination period)